Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics of Metformin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

NCT01096940
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2010 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Early Phase 1 Interventional Results available

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

NCT05081583
View directory record Official record
Conditions
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions
Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

NCT06227832
View directory record Official record
Conditions
Healthy Adults
Interventions
KP-001, Metformin, Midazolam, Clarithromycin
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

NCT02113163
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia
Interventions
Metformin Eicosapentaenoate, Metformin HCl and Vascepa
Drug
Lead sponsor
Thetis Pharmaceuticals LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

NCT00995787
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

NCT07216131
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD0780, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

NCT01111955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-823778, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hialeah, Florida • Olympia, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jun 10, 2026, 8:18 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018)

NCT07530289
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, Metformin, Ulonivirine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

NCT02803918
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baton Rouge, Louisiana • New Orleans, Louisiana • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

NCT04465877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JTT-662, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Levoketoconazole and Metformin

NCT03880825
View directory record Official record
Conditions
Healthy Subjects
Interventions
Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID)
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

NCT00970593
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
OAP-189, placebo comparator
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Chula Vista, California • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

NCT05526690
View directory record Official record
Conditions
Hypertension
Interventions
Metformin, CIN-107
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

NCT01103622
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Digoxin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2011 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2010 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 10, 2026, 8:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Jun 10, 2026, 8:18 PM EDT